Crucell files to cancel minority shares in Berna Biotech

By Lisa Kerner

Erie, Pa., April 12 - Dutch biotechnology company Crucell NV said it has filed to cancel the remaining minority held shares of Berna Biotech. Crucell holds more than 98% of Berna's shares.

The step is in line with previous announcements and the goal of fully integrating the two companies, according to a news release.

Berna Biotech plans to have its shares delisted from the Swiss Exchange upon completion of the cancellation procedure.

Crucell, based in The Netherlands, is a biotechnology company focused on research, development, production and worldwide marketing of vaccines and antibodies that combat infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.